Regeneron Pharma (REGN) PT Lowered to $1,019 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $930.90 -4.36%
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 28 | New: 13
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 28 | New: 13
Join SI Premium – FREE
Goldman Sachs analyst Salveen Richter lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,019.00 (from $1,182.00) while maintaining a Buy rating.
You May Also Be Interested In
- Pfizer (PFE) PT Raised to $40 at Argus
- Insulet Corporation (PODD) PT Raised to $200 at Jefferies
- ArcBest Corp (ARCB) PT Lowered to $146 at TD Cowen
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
